In the context of cancer biomarkers, proteins such as CA125/MUC16, Mesothelin and Enolase 2 are increasingly used not only for diagnosis and monitoring, but also as targets to evaluate therapeutic impact and prognosis in oncology. Here, MSLN is linked to cancer.